According to the Zhitong Finance App, Hengrui Pharmaceutical (600276.SH) announced that recently, the company received approval from the China Drug Administration (“China Drug Administration”) to issue a “Drug Supplement Application Approval Notice” for leviruramide tablets. The China Drug Administration approved the use of leviruramide tablets to “treat patients with metastatic hormone-sensitive prostate cancer (MHSPC) with high tumor load” from conditional approval to routine approval.

According to reports, reviverutamide tablets are second-generation AR inhibitors. Compared with first-generation AR inhibitors, they have a stronger AR inhibitory effect and have no agonizing effect. In June 2022, the company's levirudamide tablets were approved for conditional registration. In addition to the company's products, six nonsteroidal AR inhibitors, including bicalutamide and enzalutamide, have been marketed globally, and bicalutamide, enzalutamide, apatamide, and darotamide have been approved for marketing in China. According to inquiries, global sales of second-generation AR inhibitors enzalutamide, apatamide, and darotamide totaled about US$6.297 billion in 2021.